Dyne Therapeutics, Inc.
DYN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001818794
In the last 90 days, Dyne Therapeutics, Inc. insiders filed 1 open-market purchase and 8 sales; 247 institutions reported holding it in 13F filings for Q2 2026, worth $4.23B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 8, 2026, 10:59 PM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 10, 2025 | Mar 5, 2024 | Mar 2, 2023 | Mar 10, 2022 |
| Operating expenses | $468.2M | $343.9M | $242.2M | $171.0M | $150.0M |
| Research and development | $398.3M | $281.4M | $210.8M | $142.8M | $121.3M |
| Selling, general and administrative | $69.9M | $62.5M | $31.4M | $28.2M | $28.7M |
| Operating income | -$468.2M | -$343.9M | -$242.2M | -$171.0M | -$150.0M |
| Income tax | $0 | – | – | – | – |
| Net income | -$446.2M | -$317.4M | -$235.9M | -$168.1M | -$149.3M |
| EPS, basic | $-3.47 | $-3.37 | $-3.95 | $-3.23 | – |
| EPS, diluted | $-3.47 | $-3.37 | $-3.95 | $-3.23 | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 10, 2025 | Mar 5, 2024 | Mar 2, 2023 | Mar 10, 2022 |
| Cash and equivalents | $893.4M | $435.4M | $121.6M | $172.1M | $200.8M |
| Total current assets | $1.13B | $659.3M | $129.4M | $265.6M | $382.4M |
| Property, plant and equipment | $24.0M | $5.40M | $4.78M | $5.95M | $4.68M |
| Total assets | $1.19B | $691.2M | $165.1M | $306.3M | $425.7M |
| Accounts payable | $8.08M | $6.56M | $22.9M | $5.26M | $4.03M |
| Total current liabilities | $50.6M | $42.3M | $51.1M | $28.1M | $28.7M |
| Long-term debt | $148.9M | – | – | – | – |
| Total liabilities | $214.8M | $61.4M | $73.8M | $54.0M | $57.5M |
| Shareholders' equity | $972.1M | $629.8M | $91.3M | $252.4M | $368.2M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 10, 2025 | Mar 5, 2024 | Mar 2, 2023 | Mar 10, 2022 |
| Operating cash flow | -$403.2M | -$292.4M | -$188.2M | -$153.6M | -$119.6M |
| Capital expenditures | $1.92M | $2.38M | $729.0K | $3.07M | $3.62M |
| Free cash flow | -$405.1M | -$294.7M | -$188.9M | -$156.7M | -$123.2M |
| Depreciation and amortization | $2.05M | $1.67M | $1.67M | $1.68M | $1.09M |
| Stock-based compensation | $45.9M | $45.9M | $20.0M | $15.2M | $17.5M |
| Investing cash flow | -$28.8M | -$204.1M | $83.3M | $87.2M | -$137.9M |
| Financing cash flow | $890.3M | $809.9M | $54.3M | $37.4M | $157.8M |
| Net change in cash | $458.3M | $313.4M | -$50.5M | -$29.1M | -$99.6M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 30, 2026 | 187.4M | +31.2% | SEC |
| Jul 24, 2026 | 186.7M | +31.3% | SEC |
| Oct 31, 2025 | 142.8M | +40.3% | SEC |
| Jul 25, 2025 | 142.3M | +41.7% | SEC |
| Apr 25, 2025 | 113.7M | +30.1% | SEC |
| Feb 21, 2025 | 113.1M | +38.0% | SEC |
| Nov 8, 2024 | 101.8M | +65.8% | SEC |
| Aug 9, 2024 | 100.4M | +64.5% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.